European Urology Oncology Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era Joaquim Bellmunt, Emilio Esteban, Xavier García del Muro, Juan Manuel Sepúlveda, Pablo Maroto, Enrique Gallardo, Aranzazu González del Alba, Olatz Etxaniz, Marta Guix, Jose Luis González Larriba, Jose A. Arranz, Miriam Redrado, Alfonso Calvo European Urology Oncology DOI: 10.1016/j.euo.2019.07.014 Copyright © 2019 European Association of Urology Terms and Conditions
Fig. 1 Levels of circulating biomarkers analysed before treatment, after 8 wk of treatment, and at the end of the study. (A) IFNγ, (B) IL-10, (C) IL-2, (D) IL-4, and (E) TNFα. All p values < 1 are shown. European Urology Oncology DOI: (10.1016/j.euo.2019.07.014) Copyright © 2019 European Association of Urology Terms and Conditions